Greenwich LifeSciences (GLSI) said Monday it has partnered with Unicancer and its breast cancer group to activate clinical sites in France for a phase III clinical trial of the GLSI-100 immunotherapy.
The phase III study of the immunotherapy, which is being evaluated to prevent breast cancer recurrences, will be activated in 19 French sites in the UCBG breast cancer group network, the company said.
Authorities in France approved the sites in Q1 2024, Greenwich said.
Shares were down 1.7% in recent trading.
Price: 12.17, Change: -0.21, Percent Change: -1.70
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。